Jarius, Sven
Pache, Florence
Körtvelyessy, Peter
Jelčić, Ilijas
Stettner, Mark
Franciotta, Diego
Keller, Emanuela
Neumann, Bernhard
Ringelstein, Marius
Senel, Makbule
Regeniter, Axel
Kalantzis, Rea
Willms, Jan F.
Berthele, Achim
Busch, Markus
Capobianco, Marco
Eisele, Amanda
Reichen, Ina
Dersch, Rick
Rauer, Sebastian
Sandner, Katharina
Ayzenberg, Ilya
Gross, Catharina C.
Hegen, Harald
Khalil, Michael
Kleiter, Ingo
Lenhard, Thorsten
Haas, Jürgen
Aktas, Orhan
Angstwurm, Klemens
Kleinschnitz, Christoph
Lewerenz, Jan
Tumani, Hayrettin
Paul, Friedemann
Stangel, Martin
Ruprecht, Klemens
Wildemann, Brigitte
,
Funding for this research was provided by:
Ministry for Education and Research Baden-Württemberg, Germany (1499 TG93 U1)
open access publishing fund of ruprecht-karls-universität heidelberg
swiss national science foundation (4078P0_198345)
the loop - university medical research center zurich, switzerland
bih-charité clinician scientist program, funded by the charité – universitätsmedizin berlin and the berlin institute of health, berlin, germany
Universitätsklinikum Heidelberg
Article History
Received: 21 June 2021
Accepted: 2 December 2021
First Online: 20 January 2022
Declarations
:
: The study was approved by the local review boards of the participating centers. Patients gave written informed consent.
: Not applicable.
: S.J. has nothing to disclose. Fl.P. has nothing to disclose. P.K. has nothing to disclose. I.J. has received speaker honoraria or unrestricted grants from Biogen Idec and Novartis and has served as advisor for Alexion, Neuway, Merck, Novartis and Sanofi Genzyme; none of these are related to this study. M.Ste. served on the scientific advisory boards and/or received speaker honoraria, travel funding or honoraria for medical writing from UCB, Biogen Idec; Grifols, Genzyme, Roche, Merck, Novartis, Octapharma, CSL Behring, Sanofi-Aventis, TEVA, and Bayer; none related to this study. D.F. has nothing to disclose. E.K. received grants from the Swiss National Science Foundation, Swiss Innovation Promotion Agency (CTI, Innosuisse), European Commission (Eurostars), Velux, von Tobel and USZ foundations; she is member of the advisory boards of Zoll Medical, Bard Medical, Portola. B.N. has nothing to disclose. M.R. received speaker honoraria from Novartis, Bayer Vital GmbH, Roche, Alexion and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Roche, and Merck, none related to this study. M.Se. has nothing to disclose. A.R. has nothing to disclose. J.F.W. has nothing to disclose. A.B. has nothing to disclose. M.B. has nothing to disclose. M.C. received personal fees for speaking honoraria and advisory board participation by Biogen, Merck, Novartis, Sanofi, Roche. A.E. has nothing to disclose. I.R. has nothing to disclose. R.D. received lecture fees from Roche and travel grants from Biogen, none related to this study. S.R. reports receiving consulting and lecture fees, grant and research support from Bayer Vital GmbH, Biogen, Celgene, Merck Serono, Novartis, Sanofi-Aventis, Genzyme, Roche and Teva, none related to this study; furthermore, SR indicates that he is a founding executive board member of ravo Diagnostika GmbH Freiburg. K.S. has nothing to disclose. I.A. received travel grants from Biogen Idec and Guthy-Jackson Charitable Foundation, speaker honoraria from Alexion, Merck, Roche and Santhera, served on scientific advisory boards for Roche and Alexion and received research support from Diamed, none related to this manuscript. C.C.G. received speaker honoraria from Mylan, Bayer Healthcare, and Sanofi-Genzyme and travel/accommodation/meeting expenses from Bayer Healthcare, Biogen, EUROIMMUN, Novartis, and Sanofi-Genzyme; she also received research support from Biogen, Novartis, and Roche; none related to the current study. H.H. has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Siemens and Teva, and received honoraria for consulting from Biogen, Novartis and Teva. M.K. has received speaker honoraria from Bayer, Novartis, Merck, Biogen Idec and Teva Pharmaceutical Industries Ltd. and serves on scientific advisory boards for Biogen Idec, Merck Serono, Roche, Novartis, Bristol-Myers Squibb and Gilead. He received research grants from Teva Pharmaceutical Industries, Ltd., Biogen and Novartis. I.K. has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, Celgene, chugai, QVIA,Merck, Mylan, Novartis, Roche, Sanofi; none related to this study. T.L. received lecture fees from Pfizer Deutschland GmbH; he received research grants from Baxter Deutschland GmbH and from Stiftung Hospital zum Heiligen Geist Frankfurt, Germany; none related to this study. J.H. has nothing to disclose. O.A. has nothing to disclose. K.A. reports conflicts of interest not related to this paper, including speaker fees from BiogenIdec and travel grants before 2015 from Alexion, Bayer, BiogenIdec, MerckSerono, Novartis and Teva; his institution has been reimbursed for his role as a principal investigator in trials in Neuroimmunology for Alexion, Bayer, BiogenIdec, MerckSerono, Novartis and Roche. C.K. has nothing to disclose. J.L. received funding for COVID-19 research from the Ministry for Education and Research Baden-Württemberg (1499 TG93 U1); non-related to this paper, he received speaker fees or travel compensation from UCB, Bayer, Roche, Teva and the Cure Huntington’s Disease Initiative (CHDI); his institution has been reimbursed for his role as a principal investigator in trials for UCB and CHDI; his research is funded by the European Huntington’s Disease Initiative and the German Federal Ministry of Education and Research (BMBF). H.T. reports conflicts of interest not related to this publication including funding for research projects, lectures and travel from Alexion, Bayer, Biogen, Celgene, Genzyme, Fresenius, Merck, Mylan, Novartis, Roche, Siemens Health Diagnostics, and Teva, and received research support from DMSG and German Federal Ministry of Education and Research (BMBF). Fr.P. has nothing to disclose. M.Sta. has nothing to disclose. K.R. received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received speaker honoraria from Bayer and travel grants from Guthy Jackson Charitable Foundation; none of these are related to this study. B.W. received grants from the German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation and Klaus Tschira Foundation, grants and personal fees from Merck Serono, Sanofi Genzyme, Novartis pharmaceuticals, and personal fees from Alexion, Bayer, Biogen, Teva; none related to this work.